This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Elixiron Immunotherapeutics (Hong Kong) Limited. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: The Innovations of Yu-Fang Lo: A Pioneer in Antibody Technology
Introduction: Yu-Fang Lo is an accomplished inventor based in Taoyuan, Taiwan. With a keen focus on biopharmaceutical innovations, he has made significant contributions to the field of immunotherapy. His inventive efforts have garnered recognition in the scientific community, particularly through his patented work related to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Latest Patents: Yu-Fang Lo holds a noteworthy patent titled "Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof." This patent encompasses the development of anti-GM-CSF antibodies, which have the ability to bind to human GM-CSF and inhibit its biological functions. The document also outlines the pharmaceutical compositions that include these antibodies and their potential therapeutic and diagnostic applications, showcasing his commitment to advancing medical science.
Career Highlights: Yu-Fang Lo is currently employed at Elixiron Immunotherapeutics (Hong Kong) Limited, where he continues to work on innovative therapeutic solutions aimed at tackling various health challenges. Throughout his career, he has demonstrated a strong dedication to research and development in the biopharmaceutical sector, aiming to enhance patient outcomes through novel therapeutics.
Collaborations: In his professional journey, Yu-Fang Lo has collaborated with notable colleagues, including Cheng-Lun Ku and Han-Po Shih. These partnerships have fostered a creative environment that encourages the exchange of ideas and enhances the quality of research undertaken at their organization.
Conclusion: Yu-Fang Lo stands as a testament to the impact of focused innovation in the field of biopharmaceuticals. His work on anti-GM-CSF antibodies signifies a critical advancement in targeted therapies, underscoring the potential of scientific research to improve healthcare outcomes. As he continues to build on his impressive portfolio, the contributions of Yu-Fang Lo are sure to influence the future of immunotherapy.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile